Jaguar Health, Inc. 8-K

What Happened
Jaguar Health, Inc. (JAGX) reported in an 8-K that it moved from a stockholders’ deficit of approximately $18.7 million as of December 31, 2025 to having stockholders’ equity in excess of Nasdaq Listing Rule 5550(b)(1)’s $2.5 million minimum as of April 7, 2026. The company attributes this change to a series of cash and accounting items tied to agreements dated January 12, 2026 (including a License Agreement and a Supply Agreement with Napo Pharmaceuticals, Woodward Specialty LLC and Future Pak) and other receipts and gains.

Key Details

• Deficit: approximately $18.7 million stockholders’ deficit as of 12/31/2025.
• Major cash/credit items cited: $16.0M non-dilutive capital under the License Agreement; $3.0M received after termination of a buy-back provision; ~$1.0M from inventory purchase under the Supply Agreement; $2.0M contingent upon satisfaction of certain conditions; ~$1.2M from a Firm Order sale; ~$0.2M in early-2026 Mytesi sales; ~$0.2M grant revenue.
• Accounting gain: approximately $3.4M gain on extinguishment of part of debts owed to affiliates of Chicago Venture Partners, L.P.
• Timing: License and Supply Agreements dated January 12, 2026; company states equity exceeded $2.5M as of April 7, 2026. The 8-K also includes forward‑looking cautionary language.

Why It Matters
Restoring stockholders’ equity above Nasdaq’s $2.5M threshold addresses a listing‑compliance issue that could otherwise risk delisting, which is material to shareholders and marketability of the stock. The improvement is driven by a mix of contracted receipts, an inventory purchase, grant revenue, and a debt extinguishment gain—not by a single recurring revenue source. The company’s statement is framed as a belief and includes forward‑looking caveats and contingencies (e.g., certain payments conditioned on future events), so investors should review the company’s 10-K, the referenced agreements, and risk disclosures for details and verification.